Base de dados : MEDLINE
Pesquisa : D02.065.884.725.850 [Categoria DeCS]
Referências encontradas : 139 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 14 ir para página                         

  1 / 139 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27505128
[Au] Autor:Mwalwisi YH; Hoellein L; Kaale E; Holzgrabe U
[Ad] Endereço:University of Würzburg, Institute of Pharmacy and Food Chemistry, Am Hubland, Würzburg, Germany; Tanzania Food and Drug Authority, Dar es Salaam, Tanzania.
[Ti] Título:Development of a simple, rapid, and robust liquid chromatographic method for the simultaneous determination of sulfalene, sulfadoxine, and pyrimethamine in tablets.
[So] Source:J Pharm Biomed Anal;129:558-570, 2016 Sep 10.
[Is] ISSN:1873-264X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A simple, cost effective, accurate, and precise RP-HPLC method was developed for the simultaneous determination of sulfalene and sulfadoxine in fixed dose dual combinations with pyrimethamine together with their related substances. Proprietary products containing these combinations are often being prescribed in malaria endemic countries. Quantification of the active compounds and impurity profiling was achieved using two standard C18 columns with a mobile phase being composed of 60% (v/v) of a 0.05M KH2PO4 buffer solution (pH=2.6) and 40% (v/v) of methanol, applying an isocratic elution mode and a detection wavelength of 215nm. The method allows a quick quantitative determination of sulfadoxine and sulfalene and the separation of the respective impurities within a total runtime of approximately 15min and was validated with respect to specificity, linearity, precision, accuracy, limits of detection and quantification, robustness, and stability of the standard and sample solutions. The method is simpler than the corresponding method described in the International Pharmacopoeia and the United States Pharmacopoeia in terms of being easy to apply, being less time consuming, and utilizing reagents and chemicals which are cost efficient.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Pirimetamina/química
Sulfadoxina/química
Sulfaleno/química
Comprimidos/química
[Mh] Termos MeSH secundário: Estabilidade de Medicamentos
Indicadores e Reagentes/química
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Indicators and Reagents); 0 (Tablets); 88463U4SM5 (Sulfadoxine); T6BL4ZC15G (Sulfalene); Z3614QOX8W (Pyrimethamine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170808
[Lr] Data última revisão:
170808
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160810
[St] Status:MEDLINE


  2 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25400245
[Au] Autor:Kawahara T; Takahashi T; Oishi K; Tanaka H; Masuda M; Takahashi S; Takano M; Kawakami T; Fukushima K; Kanazawa H; Suzuki T
[Ad] Endereço:Department of Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan; Biofermin Kobe Research Institute, Biofermin Pharmaceutical, 7-3-4 Ibukidai-Higashimachi, Nishi-ku, Kobe, 651-2242, Japan.
[Ti] Título:Consecutive oral administration of Bifidobacterium longum MM-2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model.
[So] Source:Microbiol Immunol;59(1):1-12, 2015 Jan.
[Is] ISSN:1348-0421
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:Bifidobacterium, one of the major components of intestinal microflora, shows anti-influenza virus (IFV) potential as a probiotic, partly through enhancement of innate immunity by modulation of the intestinal immune system. Bifidobacterium longum MM-2 (MM-2), a very safe bacterium in humans, was isolated from healthy humans and its protective effect against IFV infection in a murine model shown. In mice that were intranasally inoculated with IFV, oral administration of MM-2 for 17 consecutive days improved clinical symptoms, reduced mortality, suppressed inflammation in the lower respiratory tract, and decreased virus titers, cell death, and pro-inflammatory cytokines such as IL-6 and TNF-α in bronchoalveolar lavage fluid. The anti-IFV mechanism of MM-2 involves innate immunity through significant increases in NK cell activities in the lungs and spleen and a significant increase in pulmonary gene expression of NK cell activators such as IFN-γ, IL-2, IL-12 and IL-18. Even in non-infected mice, MM-2 administration also induced significant enhancement of both IFN-γ production by Peyer's patch cells (PPs) and splenetic NK cell activity. Oral administration of MM-2 for 17 days activates systemic immunoreactivity in PPs, which contributes to innate immunity, including NK cell activation, resulting in an anti-IFV effect. MM-2 as a probiotic may function as a prophylactic agent in the management of an IFV epidemic.
[Mh] Termos MeSH primário: Bifidobacterium/imunologia
Vírus da Influenza A Subtipo H1N1/imunologia
Células Matadoras Naturais/imunologia
Infecções por Orthomyxoviridae/imunologia
Probióticos/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Animais
Citocinas/biossíntese
Modelos Animais de Doenças
Feminino
Perfilação da Expressão Gênica
Pulmão/imunologia
Pulmão/patologia
Camundongos Endogâmicos BALB C
Infecções por Orthomyxoviridae/patologia
Baço/imunologia
Sulfaleno
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cytokines); T6BL4ZC15G (Sulfalene)
[Em] Mês de entrada:1510
[Cu] Atualização por classe:150119
[Lr] Data última revisão:
150119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141118
[St] Status:MEDLINE
[do] DOI:10.1111/1348-0421.12210


  3 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25032516
[Au] Autor:Timmer MS; Sauvageau J; Foster AJ; Ryan J; Lagutin K; Shaw O; Harper JL; Sims IM; Stocker BL
[Ad] Endereço:School of Chemical and Physical Sciences, Victoria University of Wellington , P.O. Box 600, Wellington 6140, New Zealand.
[Ti] Título:Discovery of lipids from B. longum subsp. infantis using whole cell MALDI analysis.
[So] Source:J Org Chem;79(16):7332-41, 2014 Aug 15.
[Is] ISSN:1520-6904
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bifidobacteria are dominant members of the microbial community in the intestinal tract of infants, and studies have shown that glycolipids extracted from the cell surface of these bacteria elicit beneficial immune responses. Accordingly, the identification and structural characterization of glycolipids from the cell wall of bifidobacteria is the first step in correlating glycolipid structure with biological activity. Using whole cell MALDI as a screening tool, we herein present for the first time the identification and structural elucidation of the major polar lipids from Bifidobacterium longum subs. infantis. The lipids identified include an unprecedented plasmenyl cyclophosphatidic acid and a mixed acetal glycolipid, with the latter subsequently being isolated and found to suppress the innate immune response.
[Mh] Termos MeSH primário: Bifidobacterium/química
Glicolipídeos/química
Intestinos/química
Intestinos/imunologia
Intestinos/microbiologia
Lipídeos/química
Sulfaleno/química
[Mh] Termos MeSH secundário: Aderência Bacteriana/imunologia
Bifidobacterium/imunologia
Bifidobacterium/metabolismo
Glicolipídeos/metabolismo
Seres Humanos
Lipídeos/imunologia
Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Glycolipids); 0 (Lipids); T6BL4ZC15G (Sulfalene)
[Em] Mês de entrada:1502
[Cu] Atualização por classe:140816
[Lr] Data última revisão:
140816
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140718
[St] Status:MEDLINE
[do] DOI:10.1021/jo501016c


  4 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21934646
[Au] Autor:Boechat N; Pinheiro LC; Santos-Filho OA; Silva IC
[Ad] Endereço:Departamento de Sintese Organica, Instituto de Tecnologia em Farmacos, Fundacao Oswaldo Cruz, Manguinhos, CEP 21041-250, Rio de Janeiro, RJ, Brazil. boechat@far.fiocruz.br
[Ti] Título:Design and synthesis of new N-(5-trifluoromethyl)-1H-1,2,4-triazol-3-yl benzenesulfonamides as possible antimalarial prototypes.
[So] Source:Molecules;16(9):8083-97, 2011 Sep 20.
[Is] ISSN:1420-3049
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:A rational approach was used to synthesize a new set of 15 1H-1,2,4-triazol-3-yl benzenesulfonamide derivatives with the aim of developing new antimalarial lead compounds. These derivatives were prepared in yields between 50% and 62%, and their structures were elucidated using IR, ¹H-, ¹³C-, ¹9F-NMR, MS and elemental analysis. A docking study based on sulfonamides previously used against malaria identified trifluoromethyl-substituted derivatives to be the best lead compounds for new antimalarial drug development.
[Mh] Termos MeSH primário: Antimaláricos/síntese química
Compostos de Flúor/síntese química
Sulfonamidas/síntese química
Triazóis/síntese química
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Antimaláricos/química
Domínio Catalítico
Simulação por Computador
Sequência Conservada
Ciclização
Di-Hidropteroato Sintase/química
Desenho de Drogas
Compostos de Flúor/química
Ligações de Hidrogênio
Espectroscopia de Ressonância Magnética
Modelos Moleculares
Dados de Sequência Molecular
Estrutura Molecular
Plasmodium falciparum/enzimologia
Ligação Proteica
Sulfadiazina/química
Sulfadoxina/química
Sulfaleno/química
Sulfonamidas/química
Termodinâmica
Triazóis/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antimalarials); 0 (Fluorine Compounds); 0 (Sulfonamides); 0 (Triazoles); 0N7609K889 (Sulfadiazine); 88463U4SM5 (Sulfadoxine); 98-10-2 (benzenesulfonamide); EC 2.5.1.15 (Dihydropteroate Synthase); T6BL4ZC15G (Sulfalene)
[Em] Mês de entrada:1112
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110922
[St] Status:MEDLINE
[do] DOI:10.3390/molecules16098083


  5 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21700239
[Au] Autor:Fortin A; Jansen FH
[Ti] Título:ACTs for the treatment of schistosomiasis.
[So] Source:Lancet Infect Dis;11(7):498, 2011 Jul.
[Is] ISSN:1474-4457
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anti-Helmínticos/administração & dosagem
Artemisininas/administração & dosagem
Pirimetamina/administração & dosagem
Schistosoma mansoni
Esquistossomose mansoni/tratamento farmacológico
Sulfaleno/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Seres Humanos
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Anthelmintics); 0 (Artemisinins); 60W3249T9M (artesunate); T6BL4ZC15G (Sulfalene); Z3614QOX8W (Pyrimethamine)
[Em] Mês de entrada:1109
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110625
[St] Status:MEDLINE
[do] DOI:10.1016/S1473-3099(11)70157-8


  6 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:21443809
[Au] Autor:Jansen FH
[Ad] Endereço:ACT-ion Afrique, Brussels, Belgium. fhjansen@actionafrique.com
[Ti] Título:Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination.
[So] Source:Malar J;10:70, 2011 Mar 29.
[Is] ISSN:1475-2875
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Recent publications put a serious warning regarding the inefficacy of sulphadoxine-pyrimethamine (SP) for the intermittent preventive treatment of malaria in young children (IPTi). Recommendations for other therapies are being made. By using a different and better sulphonamide (sulphamethoxypyrazine), it is possible to manufacture fixed dose combination pills with artesunate and pyrimethamine. This combination permits a full therapy over 24 hours (dosing interval being 12 hours). It is recommended that this combination should be tested in future field studies of IPTi.
[Mh] Termos MeSH primário: Antimaláricos/administração & dosagem
Artemisininas/administração & dosagem
Malária/tratamento farmacológico
Malária/prevenção & controle
Pirimetamina/administração & dosagem
Sulfaleno/administração & dosagem
[Mh] Termos MeSH secundário: Antimaláricos/uso terapêutico
Artemisininas/uso terapêutico
Criança
Combinação de Medicamentos
Resistência a Múltiplos Medicamentos
Feminino
Seres Humanos
Lactente
Plasmodium/efeitos dos fármacos
Pirimetamina/uso terapêutico
Sulfaleno/uso terapêutico
[Pt] Tipo de publicação:EDITORIAL
[Nm] Nome de substância:
0 (Antimalarials); 0 (Artemisinins); 0 (Drug Combinations); 60W3249T9M (artesunate); T6BL4ZC15G (Sulfalene); Z3614QOX8W (Pyrimethamine)
[Em] Mês de entrada:1108
[Cu] Atualização por classe:150204
[Lr] Data última revisão:
150204
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110330
[St] Status:MEDLINE
[do] DOI:10.1186/1475-2875-10-70


  7 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:21194422
[Au] Autor:Ayede IA; Falade AG; Sowunmi A; Jansen FH
[Ad] Endereço:Department of Paediatrics, College of Medicine, University College Hospital, Ibadan, Nigeria. idayede@yahoo.co.uk
[Ti] Título:An open randomized clinical trial in comparing two artesunate-based combination treatments on Plasmodium falciparum malaria in Nigerian children: artesunate/sulphamethoxypyrazine/pyrimethamine (fixed dose over 24 hours) versus artesunate/amodiaquine (fixed dose over 48 hours).
[So] Source:Malar J;9:378, 2010 Dec 31.
[Is] ISSN:1475-2875
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Several studies have demonstrated the efficacy of artemisinin-combination therapy (ACT) across malaria zones of the world. Fixed dose ACT with shorter courses and fewer tablets may be key determinants to ease of administration and compliance. METHODS: Children aged one year to 13 years presenting with uncomplicated Plasmodium falciparum malaria were recruited in Ibadan, south-western Nigeria. A total of 250 children each were randomly assigned to receive three doses of artesunate/sulphamethoxypyrazine/pyrimethamine (AS + SMP) (12 hourly doses over 24 hours) or three doses of artesunate/amodiaquine (AS + AQ) (daily doses over 48 hours). Efficacy and safety of the two drugs were assessed using a 28-day follow-up and the primary outcome was PCR- corrected parasitological cure rate and clinical response. RESULTS: There were two (0.4%) early treatment failures, one in each treatment arm. The PCR corrected cure rates for day 28 was 97.9% in the AS + AQ arm and 95.6% in the AS + SMP arm (p = 0.15). The re-infection rate was 1.7% in the AS + AQ arm and 5.7% in the AS + SMP arm (p = 0.021). The fever clearance time was similar in the two treatment groups: 1 - 2 days for both AS + SMP and AS + AQ (p = 0.271). The parasite clearance time was also similar in the two treatment groups with 1 - 7 days for AS + SMP and 1 - 4 days for AS + AQ (p = 0.941). The proportion of children with gametocytes over the follow-up period was similar in both treatment groups. Serious Adverse Events were not reported in any of the patients and in all children, laboratory values (packed cell volume, liver enzymes, bilirubin) remained within normal levels during the follow-up period but the packed cell volume was significantly lower in the AS + SMP group. CONCLUSIONS: This study demonstrates that AS + SMP FDC given as three doses over 24 hours (12-hour intervals) has similar efficacy as AS + AQ FDC given as three doses over 48 hours (24-hour interval) for the treatment of uncomplicated Plasmodium falciparum malaria in children in Nigeria. Both drugs also proved to be safe. Therefore, AS + SMP could be an alternative to currently recommended first-line ACT with continuous resistance surveillance.
[Mh] Termos MeSH primário: Antimaláricos/administração & dosagem
Artemisininas/administração & dosagem
Malária Falciparum/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Amodiaquina/administração & dosagem
Amodiaquina/efeitos adversos
Antimaláricos/efeitos adversos
Artemisininas/efeitos adversos
Criança
Pré-Escolar
Quimioterapia Combinada/efeitos adversos
Quimioterapia Combinada/métodos
Feminino
Seres Humanos
Lactente
Masculino
Nigéria
Pirimetamina/administração & dosagem
Pirimetamina/efeitos adversos
Sulfaleno/administração & dosagem
Sulfaleno/efeitos adversos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antimalarials); 0 (Artemisinins); 220236ED28 (Amodiaquine); 60W3249T9M (artesunate); T6BL4ZC15G (Sulfalene); Z3614QOX8W (Pyrimethamine)
[Em] Mês de entrada:1103
[Cu] Atualização por classe:150205
[Lr] Data última revisão:
150205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110104
[St] Status:MEDLINE
[do] DOI:10.1186/1475-2875-9-378


  8 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:20705516
[Au] Autor:Obonyo CO; Muok EM; Mwinzi PN
[Ad] Endereço:Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
[Ti] Título:Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: an open-label randomised controlled trial.
[So] Source:Lancet Infect Dis;10(9):603-11, 2010 Sep.
[Is] ISSN:1474-4457
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Schistosomiasis is an important parasitic disease in Kenya. Decreasing susceptibility of schistosomes to praziquantel, the major drug used to reduce disease morbidity, has made assessment of new antischistosomal drugs a priority. We aimed to assess the safety and efficacy of an artesunate-based combination drug in the treatment of schistosomiasis. METHODS: In this open-label randomised trial in Rarieda district of western Kenya, we enrolled school children (aged 6-15 years) who had Schistosoma mansoni infection according to duplicate Kato-Katz thick smears from a stool sample. Computer-generated block randomisation was used to assign children (1:1) to receive artesunate (100 mg) with sulfalene (also known as sulfamethoxypyrazine; 250 mg) plus pyrimethamine (12.5 mg) as one dose every 24 h for 3 days or one dose of praziquantel (40 mg/kg per day). The primary efficacy endpoint was the number of participants cured 28 days after treatment. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01054651. RESULTS: Between October and December, 2009, 212 children were enrolled and assigned to receive artesunate with sulfalene plus pyrimethamine (n=106) or praziquantel (n=106). 69 patients (65%) were cured in the praziquantel treatment group compared with 15 (14%) in the artesunate with sulfalene plus pyrimethamine treatment group (p<0.0001). Adverse events were less common in patients taking artesunate with sulfalene plus pyrimethamine than in those taking praziquantel (22% [n=23] vs 49% [n=52], p<0.0001), and no drug-related serious adverse events occurred. INTERPRETATION: The standard treatment with praziquantel is more effective than artesunate with sulfalene plus pyrimethamine in the treatment of children with S mansoni infection in western Kenya. Whether artemisinin-based combination therapy has a role in the treatment of schistosomiasis is unclear.
[Mh] Termos MeSH primário: Artemisininas/uso terapêutico
Pirimetamina/uso terapêutico
Esquistossomose mansoni/tratamento farmacológico
Sulfaleno/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Amebicidas/efeitos adversos
Amebicidas/uso terapêutico
Animais
Antiprotozoários/efeitos adversos
Antiprotozoários/uso terapêutico
Artemisininas/efeitos adversos
Criança
Pré-Escolar
Quimioterapia Combinada
Feminino
Seres Humanos
Lactente
Quênia
Masculino
Pirimetamina/efeitos adversos
Schistosoma mansoni
Esquistossomose mansoni/classificação
Sulfaleno/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Amebicides); 0 (Antiprotozoal Agents); 0 (Artemisinins); 60W3249T9M (artesunate); T6BL4ZC15G (Sulfalene); Z3614QOX8W (Pyrimethamine)
[Em] Mês de entrada:1009
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100814
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1016/S1473-3099(10)70161-4


  9 / 139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20144932
[Au] Autor:Okafor HU; Shu EN; Oguonu T
[Ad] Endereço:Department of Paediatrics, College of Medicine, University of Nigeria, Enugu, Nigeria. huche57@yahoo.com
[Ti] Título:Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance.
[So] Source:J Trop Pediatr;56(6):398-406, 2010 Dec.
[Is] ISSN:1465-3664
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Combination therapy with artemesinin or non-artemesinin-based antimalarials (ACTs or NACTs) are known to retard the development and progression of drug resistance in Plasmodium falciparum (P. falciparum). The optimal antimalarial combinations in Africa are yet unknown. We evaluate the therapeutic efficacy and effects on gametocyte carriage of Artemether-Lumefantrine (AL) and Amodiaquine-Sulfalene/Pyrimethamine (ASP) in children with P. falciparum malaria in an endemic area. One-hundred and thirty-nine children aged ≤ 10 years with uncomplicated P. falciparum malaria were enrolled. The primary end points were adequate clinical and parasitological response (ACPR), late parasitological failure(LPF), late clinical failure (LCF) and early treatment failure (ETF). Polymerase chain reaction (PCR)-corrected cure rates on days 14-42 and gametocyte carriage rates were determined. Fever clearance time was significantly shorter (P = 0.009) with ASP, but parasite clearance time was similar with both regimens. Day 28 cure rates were 91.4 and 89.9% (PCR-corrected) for AL and ASP respectively. Both regimens were well tolerated. Overall, gametocyte carriage before and following treatment were similar. Both combinations were found effective and comparable for treatment of acute, uncomplicated, P. falciparum malaria.
[Mh] Termos MeSH primário: Antimaláricos/uso terapêutico
Artemisininas/uso terapêutico
Gametogênese/efeitos dos fármacos
Malária Falciparum/tratamento farmacológico
Plasmodium falciparum/efeitos dos fármacos
[Mh] Termos MeSH secundário: Amodiaquina/uso terapêutico
Pré-Escolar
Cloroquina/administração & dosagem
Combinação de Medicamentos
Resistência a Medicamentos
Quimioterapia Combinada
Etanolaminas/uso terapêutico
Feminino
Fluorenos/uso terapêutico
Seguimentos
Seres Humanos
Lactente
Malária Falciparum/parasitologia
Masculino
Nigéria
Plasmodium falciparum/genética
Plasmodium falciparum/crescimento & desenvolvimento
Reação em Cadeia da Polimerase
Pirimetamina/uso terapêutico
Sulfaleno/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antimalarials); 0 (Artemisinins); 0 (Drug Combinations); 0 (Ethanolamines); 0 (Fluorenes); 0 (artemether-lumefantrine combination); 220236ED28 (Amodiaquine); 886U3H6UFF (Chloroquine); 9RMU91N5K2 (artemisinine); C7D6T3H22J (artemether); F38R0JR742 (lumefantrine); T6BL4ZC15G (Sulfalene); Z3614QOX8W (Pyrimethamine)
[Em] Mês de entrada:1101
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100211
[St] Status:MEDLINE
[do] DOI:10.1093/tropej/fmq004


  10 / 139 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
PubMed Central Texto completo
Texto completo
[PMID]:19802383
[Au] Autor:Sissoko MS; Dabo A; Traoré H; Diallo M; Traoré B; Konaté D; Niaré B; Diakité M; Kamaté B; Traoré A; Bathily A; Tapily A; Touré OB; Cauwenbergh S; Jansen HF; Doumbo OK
[Ad] Endereço:Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Odonto-Stomatology, Malaria Research and Training Center, University of Bamako, Bamako, Mali. mssissoko@mrtcbko.org
[Ti] Título:Efficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children.
[So] Source:PLoS One;4(10):e6732, 2009 Oct 05.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This study was conducted to determine the efficacy of the antimalarial artemisinin-based combination therapy (ACT) artesunate +sulfamethoxypyrazine/pyrimethamine (As+SMP), administered in doses used for malaria, to treat Schistosoma haematobium in school aged children. METHODOLOGY/PRINCIPAL FINDINGS: The study was conducted in Djalakorodji, a peri-urban area of Bamako, Mali, using a double blind setup in which As+SMP was compared with praziquantel (PZQ). Urine samples were examined for Schistosoma haematobium on days -1, 0, 28 and 29. Detection of haematuria, and haematological and biochemical exams were conducted on day 0 and day 28. Clinical exams were performed on days 0, 1, 2, and 28. A total of 800 children were included in the trial. The cure rate obtained without viability testing was 43.9% in the As+SMP group versus 53% in the PZQ group (Chi(2) = 6.44, p = 0.011). Egg reduction rates were 95.6% with PZQ in comparison with 92.8% with As+SMP, p = 0.096. The proportion of participants who experienced adverse events related to the medication was 0.5% (2/400) in As+SMP treated children compared to 2.3% (9/399) in the PZQ group (p = 0.033). Abdominal pain and vomiting were the most frequent adverse events in both treatment arms. All adverse events were categorized as mild. CONCLUSIONS/SIGNIFICANCE: The study demonstrates that PZQ was more effective than As+SMP for treating Schistosoma haematobium. However, the safety and tolerability profile of As+SMP was similar to that seen with PZQ. Our findings suggest that further investigations seem justifiable to determine the dose/efficacy/safety pattern of As+SMP in the treatment of Schistosoma infections. TRIAL REGISTRATION: ClinicalTrials.gov NCT00510159.
[Mh] Termos MeSH primário: Antimaláricos/uso terapêutico
Artemisininas/administração & dosagem
Combinação de Medicamentos
Praziquantel/administração & dosagem
Schistosoma haematobium/metabolismo
Esquistossomose Urinária/tratamento farmacológico
Sulfaleno/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Animais
Criança
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Pirimetamina/administração & dosagem
Fatores de Tempo
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antimalarials); 0 (Artemisinins); 0 (Drug Combinations); 60W3249T9M (artesunate); 6490C9U457 (Praziquantel); T6BL4ZC15G (Sulfalene); Z3614QOX8W (Pyrimethamine)
[Em] Mês de entrada:1003
[Cu] Atualização por classe:161215
[Lr] Data última revisão:
161215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:091006
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0006732



página 1 de 14 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde